Health and wellness products company Herbalife (NYSE:HLF) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 2.7% year on year to $1.27 billion. The company expects next quarter’s revenue to be around $1.25 billion, close to analysts’ estimates. Its non-GAAP profit of $0.50 per share was 8.4% above analysts’ consensus estimates.
Is now the time to buy HLF? Find out in our full research report (it’s free for active Edge members).
Herbalife (HLF) Q3 CY2025 Highlights:
- Revenue: $1.27 billion vs analyst estimates of $1.27 billion (2.7% year-on-year growth, 0.5% beat)
- Adjusted EPS: $0.50 vs analyst estimates of $0.46 (8.4% beat)
- Adjusted EBITDA: $163 million vs analyst estimates of $158.2 million (12.8% margin, 3% beat)
- Revenue Guidance for Q4 CY2025 is $1.25 billion at the midpoint, roughly in line with what analysts were expecting
- EBITDA guidance for the full year is $650 million at the midpoint, in line with analyst expectations
- Operating Margin: 9.9%, in line with the same quarter last year
- Organic Revenue rose 2.7% year on year vs analyst estimates of 2.4% growth (34.6 basis point beat)
- Market Capitalization: $849.6 million
StockStory’s Take
Herbalife’s third quarter saw sales growth return in North America and globally, marking a notable shift after several quarters of flat or declining performance in key markets. Management credited this to disciplined execution and renewed distributor engagement, particularly in North America, where new distributor growth reached 17%. CEO Stephan Gratziani cited the role of product launches like Multiburn and ongoing programs such as the Diamond Development Mastermind in energizing distributors, stating, “This is a significant milestone…a reflection of nearly two years of disciplined execution and foundational work across every level of the business.”
Looking forward, Herbalife’s management expects continued momentum from technology-driven initiatives, including the commercial release of its Pro2col personalized health platform and further expansion of its HL/Skin line. The company plans to introduce at-home biomarker testing and personalized nutritional supplements, with beta access targeted for U.S. distributors in the coming quarters. CFO John DeSimone emphasized the company’s intent to leverage both digital tools and its direct sales network, noting, “We believe there is a big place in the future for subscription revenue,” indicating a potential shift in revenue streams as new offerings mature.
Key Insights from Management’s Remarks
Management pointed to North America’s distributor-led recovery, the launch of new wellness products, and the company’s increased use of technology as primary drivers of the quarter’s performance.
- North America distributor resurgence: Herbalife achieved its first sales growth in North America since 2021, driven by renewed distributor recruitment, expanded training programs, and excitement around new product launches. Management highlighted that initiatives like the Premier League and Mastermind programs have improved distributor performance and engagement.
- Technology-enabled personalization: The Pro2col platform, currently in beta with 7,900 distributors, is central to Herbalife’s vision of personalized nutrition. Features such as the Pro2score wellness assessment and AI-driven coaching tools are designed to deepen customer engagement and encourage consistent product usage. Management sees strong engagement metrics as an early indicator that this platform will support future sales growth.
- Product innovation pipeline: Several products launched this quarter, including the HL/Skin K-beauty line in EMEA and Multiburn for weight management in the U.S., align with growing consumer interest in personalized wellness and functional nutrition. These launches were supported by AI-driven assessment tools and rapid integration into distributor routines.
- Expansion of training and leadership programs: The Diamond Development Mastermind and other leadership initiatives expanded to new markets such as India, aiming to strengthen the distributor pipeline and ensure sustainable growth. Management reported positive feedback and increased participation, supporting confidence in broader rollout.
- Operational discipline and debt reduction: Herbalife continued to generate strong cash flow, repaying significant debt and reducing leverage ahead of targets. Management reiterated that excess cash would prioritize supporting new business strategies and further debt paydown over stock buybacks in the near term.
Drivers of Future Performance
Herbalife’s outlook is anchored by investments in digital engagement, new product launches, and the scaling of personalized health offerings, though margin pressures and regional demand shifts remain key considerations.
- Subscription and digital platform growth: Management believes that the rollout of subscription-based offerings through platforms like Pro2col and forthcoming personalized supplement plans will provide more predictable revenue streams and deepen customer retention. The integration of AI and at-home biomarker testing is expected to differentiate Herbalife from digital-only competitors.
- Operational cost headwinds: While pricing actions and product mix improvements support margins, management cautioned that foreign exchange volatility, higher input costs, and normalization of bonus accruals could create near-term margin pressure, particularly in the next quarter. Continued investment in technology and distributor training is expected to weigh on SG&A expenses.
- Regional performance variability: Growth is anticipated to be uneven across markets, with North America and Latin America showing strength, while China continues to post volume declines. Management aims to offset regional challenges through targeted product launches and localized distributor engagement strategies.
Catalysts in Upcoming Quarters
In the coming quarters, our team will be watching (1) the commercial rollout and user adoption rates for the Pro2col personalized health platform, (2) the expansion and performance of new product lines such as HL/Skin and Multiburn across additional markets, and (3) the company’s ability to sustain distributor engagement and leadership development initiatives. Execution on margin management and the transition toward subscription-based business models will also be closely monitored as potential indicators of sustainable growth.
Herbalife currently trades at $8.72, up from $8.30 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free for active Edge members).
High Quality Stocks for All Market Conditions
Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.
The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.